Evidence map›Paper›PMID 41291592›Full record

ArticleBMC cancer2025

Development and validation of NTCP models for predicting acute esophagitis in carbon ion radiotherapy for thoracic malignancies.

Yongqiang Li, Liwen Zhang, Yuqi Liu, Ningyi Ma, Kai-Liang Wu, Jingfang Mao, Jian Chen

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongqiang Li *Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China.
Liwen Zhang *Department of Medical Physics, Shanghai Proton and Heavy Ion Center, Shanghai, 201321, China.
Yuqi LiuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, 201321, China.
Ningyi MaDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China.
Kai-Liang WuDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China.
Jingfang MaoDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China. jingfang.mao@sphic.org.cn.
Jian ChenDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, 201321, China. jian.chen@sphic.org.cn.

Funding

Shanghai Municipal Health Commission Funds 202140009 and 202240052Shanghai Pudong New Area Health Commission Funds PW PW2022A-29, PW2023A-10 and PW2024A-40Shanghai Pudong New Area Science and Technology Development Fund for the People's Livelihood Research Project PKJ2023-Y41, PKJ2023-Y43 and PKJ2024-Y59
6 · The paper itself

Abstract

backgroundAcute esophagitis (AE) is a common toxicity following carbon ion radiotherapy (CIRT) for thoracic malignancies (TM). Despite CIRT’s physical advantages, specific normal tissue complication probability (NTCP) models for predicting AE remain underdeveloped. PURPOSE: This study aims to develop NTCP models using clinical data to identify key risk factors for AE during CIRT, enabling personalized treatment optimization to reduce esophageal toxicity.

methods168 patients with TM (non-small cell lung cancer (NSCLC): 95, tracheobronchial adenoid cystic carcinoma (TACC): 43, thoracic bone and soft tissue sarcomas (TBSTS): 30) treated with CIRT (59.5–80 Gy (RBE) in 16–23 fractions) were analyzed. AE was graded per Common Terminology Criteria for Adverse Events v4.03. Dosimetric parameters and clinical variables were evaluated using logistic regression. The Lyman-Kutcher-Burman (LKB) NTCP model was optimized via maximum likelihood estimation to establish volume effect (n), slope (m), and tolerance dose for 50% complication probability (TD50) parameters. Model performance was assessed by the area under curve (AUC) of the receiver operating characteristic (ROC) curve and validated internally using 1000-fold bootstrapping.

resultsNo grade ≥ 3 AE was observed. TACC showed highest rates (G1:88.4%; G2:20.9%), followed by TBSTS (G1:50.0%; G2:16.7%) and NSCLC (G1:35.8%; G2:1.1%). Females had higher G1 (63.0% vs. 47.5%) but doubled G2 risk (13.0% vs. 7.4%) versus males. Toxicity peaked in patients < 60 years (G1:64.4%; G2:16.4%), declining with age. Paradoxically, non-drinkers had 9-fold higher G2 risk (14.0% vs. 1.5%), while smoking showed protection (non-smokers vs. smokers, G2:1.2% vs. 17.1%). Notably, multivariate analysis identified V44Gy (RBE) as the independent predictor for G1 AE (OR: 1.06, 95% CI: 1.013–1.115; p < 0.001) with AUC 0.83. While G2 toxicity was driven by D9cc (1.07, 1.02–1.13; p = 0.004), age years (0.94, 0.895–0.986; p = 0.012), and smoking status (0.12, 0.013–1.04; p = 0.05) with AUC 0.936.The LKB models demonstrated for G1 AE: n = 0.23 (95% CI:0.05–0.45), m = 0.81 (0.2-1.0), TD50 = 62.8 Gy (RBE) (35.5–75.5) with AUC = 0.792, and for Grade 2 AE: n = 0.06 (0.01–0.20), m = 0.16 (0.01–0.25), TD50 = 80 Gy (RBE) (50.0–95.0) with AUC = 0.764.

conclusionsThe first validated NTCP models for CIRT-induced AE highlight V44Gy (RBE), D9cc, age, and smoking as critical predictors. Derived LKB parameters enable personalized planning to reduce esophageal toxicity, advancing particle therapy optimization.

Indexed as

EsophagitisHeavy Ion RadiotherapyRadiation InjuriesThoracic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRisk FactorsROC CurveAcute esophagitisCarbon ion radiotherapyDose constraintsNormal tissue complication probability modelsThoracic tumors

Identifiers

PMID41291592
PMCPMC12777465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.